Biosidus has developed and commercialized nine biosimilar products in the last 30 years, with all work being done in-house at its facilities in Argentina. The company is currently advancing a 10th biosimilar — agalsidase beta for the treatment of Fabry disease — which is in phase III clinical trials and scheduled to be commercially launched in 2025. In 2024 they began offering CDMO services for their excess capacity in microbial and mammalian biologics, and sterile manufacturing.
